Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 173401, 11 pages
http://dx.doi.org/10.1155/2014/173401
Research Article

Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer

1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
2Department of Public Health, Kaohsiung Medical University, Kaohsiung 807, Taiwan
3Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Chiayi City 613, Taiwan
4Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
5Roswell Park Cancer Institute, Buffalo, NY 14263, USA
6Basic Science, Nursing Department, Meiho University, Pingtung 900, Taiwan
7Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
8Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
9Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan
10Divisions of General Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan

Received 2 April 2014; Revised 4 June 2014; Accepted 9 June 2014; Published 29 June 2014

Academic Editor: Noriyoshi Sawabata

Copyright © 2014 Chin-Chou Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, M. M. Center, C. DeSantis, and E. M. Ward, “Global patterns of cancer incidence and mortality rates and trends,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 8, pp. 1893–1907, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. S. Ramalingam, T. K. Owonikoko, and F. R. Khuri, “Lung cancer: new biological insights and recent therapeutic advances,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 91–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. G. Favaretto, G. Pasello, and C. Magro, “Second and third line treatment in advanced non-small cell lung cancer,” Discovery Medicine, vol. 8, no. 43, pp. 204–209, 2009. View at Google Scholar · View at Scopus
  4. P. M. Marcus, E. J. Bergstralh, R. M. Fagerstrom et al., “Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up,” Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1308–1316, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Maione, A. Rossi, P. C. Sacco, M. A. Bareschino, C. Schettino, and C. Gridelli, “Advances in chemotherapy in advanced non-small-cell lung cancer,” Expert Opinion on Pharmacotherapy, vol. 11, no. 18, pp. 2997–3007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier, J. Pignon, and J. Vansteenkiste, “Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer,” New England Journal of Medicine, vol. 350, no. 4, pp. 351–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. Spiro and G. A. Silvestri, “One hundred years of lung cancer,” The American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 523–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. T. E. Stinchcombe and M. A. Socinski, “Maintenance therapy in advanced non-small cell lung cancer: current status and future implications,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 174–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. N. K. Veeramachaneni, R. H. Feins, B. J. K. Stephenson, L. J. Edwards, and F. G. Fernandez, “Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America,” Annals of Thoracic Surgery, vol. 94, no. 3, pp. 922–928, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. S. Herbst, A. Onn, and A. Sandler, “Angiogenesis and lung cancer: prognostic and therapeutic implications,” Journal of Clinical Oncology, vol. 23, no. 14, pp. 3243–3256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. D. Chanin, D. T. Merrick, W. A. Franklin, and F. R. Hirsch, “Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present,” Current Opinion in Pulmonary Medicine, vol. 10, no. 4, pp. 242–247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Hassanein, J. C. Callison, C. Callaway-Lane, M. C. Aldrich, E. L. Grogan, and P. P. Massion, “The state of molecular biomarkers for the early detection of lung cancer,” Cancer Prevention Research, vol. 5, no. 8, pp. 992–1006, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. A. Mostefai, R. Andriantsitohaina, and M. C. Martínez, “Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer,” Physiological Research, vol. 57, no. 3, pp. 311–320, 2008. View at Google Scholar · View at Scopus
  15. Z. Mallat, H. Benamer, B. Hugel et al., “Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes,” Circulation, vol. 101, no. 8, pp. 841–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Martin, A. Tesse, B. Hugel et al., “Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression,” Circulation, vol. 109, no. 13, pp. 1653–1659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. C. Martínez, A. Tesse, F. Zobairi, and R. Andriantsitohaina, “Shed membrane microparticles from circulating and vascular cells in regulating vascular function,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 288, no. 3, pp. H1004–H1009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Mezentsev, R. M. H. Merks, E. O'Riordan et al., “Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 289, no. 3, pp. H1106–H1114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Martínez, F. Larbret, F. Zobairi et al., “Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens,” Blood, vol. 108, no. 9, pp. 3012–3020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Nomura, Y. Ozaki, and Y. Ikeda, “Function and role of microparticles in various clinical settings,” Thrombosis Research, vol. 123, no. 1, pp. 8–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. F. A. Zwaal and A. J. Schroit, “Pathophysiologic implications of membrane phospholipid asymmetry in blood cells,” Blood, vol. 89, no. 4, pp. 1121–1132, 1997. View at Google Scholar · View at Scopus
  22. L. L. Horstman and Y. S. Ahn, “Platelet microparticles: a wide-angle perspective,” Critical Reviews in Oncology/Hematology, vol. 30, no. 2, pp. 111–142, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Nomura, “Function and clinical significance of platelet-derived microparticles,” International Journal of Hematology, vol. 74, no. 4, pp. 397–404, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Nomura, S. Uehata, S. Saito, K. Osumi, Y. Ozeki, and Y. Kimura, “Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome,” Thrombosis and Haemostasis, vol. 89, no. 3, pp. 506–512, 2003. View at Google Scholar · View at Scopus
  25. K. Joop, R. J. Berckmans, R. Nieuwland et al., “Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms,” Thrombosis and Haemostasis, vol. 85, no. 5, pp. 810–820, 2001. View at Google Scholar · View at Scopus
  26. N. Ogata, M. Imaizumi, S. Nomura et al., “Increased levels of platelet-derived microparticles in patients with diabetic retinopathy,” Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 193–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Daniel, F. Fakhouri, D. Joly et al., “Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis,” Kidney International, vol. 69, no. 8, pp. 1416–1423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. E. T. Tesselaar, F. P. H. T. M. Romijn, I. K. van der Linden, F. A. Prins, R. M. Bertina, and S. Osanto, “Microparticle-associated tissue factor activity: a link between cancer and thrombosis?” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 520–527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Nomura, H. Kagawa, Y. Ozaki, M. Nagahama, C. Yoshimura, and S. Fukuhara, “Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies,” Thrombosis Research, vol. 95, no. 5, pp. 205–213, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Janowska-Wieczorek, L. A. Marquez-Curtis, M. Wysoczynski, and M. Z. Ratajczak, “Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells,” Transfusion, vol. 46, no. 7, pp. 1199–1209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kanazawa, S. Nomura, M. Kuwana, M. Muramatsu, K. Yamaguchi, and S. Fukuhara, “Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer,” Lung Cancer, vol. 39, no. 2, pp. 145–149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. C.-C. Tseng, C.-C. Wang, H.-C. Chang et al., “Levels of circulating microparticles in lung cancer patients and possible prognostic value,” Disease Markers, vol. 35, no. 5, pp. 301–310, 2013. View at Publisher · View at Google Scholar
  33. S. B. Edge and C. C. Compton, “The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Dey-Hazra, B. Hertel, T. Kirsch et al., “Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing,” Vascular Health and Risk Management, vol. 6, no. 1, pp. 1125–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Leu, H.-I. Lu, C.-K. Sun et al., “Retention of endothelial progenitor cells in bone marrow in a murine model of endogenous tissue plasminogen activator (tPA) deficiency in response to critical limb ischemia,” International Journal of Cardiology, vol. 170, no. 3, pp. 394–405, 2014. View at Publisher · View at Google Scholar
  36. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Oken, R. H. Creech, D. C. Tormey et al., “Toxicology and response criteria of the eastern cooperative oncology group,” The American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 6, pp. 649–655, 1982. View at Google Scholar · View at Scopus
  38. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Giusti, S. D'Ascenzo, and V. Dolo, “Microvesicles as potential ovarian cancer biomarkers,” BioMed Research International, vol. 2013, Article ID 703048, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Fleitas, V. Martínez-Sales, V. Vila et al., “Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer,” PLoS ONE, vol. 7, no. 10, Article ID e47365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. L. A. Stewart and J. P. Pignon, “Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials,” British Medical Journal, vol. 311, no. 7010, pp. 899–909, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. S. J. Mandrekar, S. E. Schild, S. L. Hillman et al., “A prognostic model for advanced stage nonsmall cell lung cancer: pooled analysis of north central cancer treatment group trials,” Cancer, vol. 107, no. 4, pp. 781–792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. J. Park, J. Lee, J. Y. Hong et al., “Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment,” Cancer, vol. 115, no. 7, pp. 1518–1530, 2009. View at Publisher · View at Google Scholar
  44. T. Berghmans, M. Paesmans, and J. P. Sculier, “Prognostic factors in stage III non-small lung cancer: a review of conventional, metabolic and new biological variables,” Therapeutic Advances in Medical Oncology, vol. 3, no. 3, pp. 127–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber, “Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 587–595, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. H. S. Shim, D. H. Lee, E. J. Park, and S. H. Kim, “Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the international association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification,” Archives of Pathology and Laboratory Medicine, vol. 135, no. 10, pp. 1329–1334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Baj-Krzyworzeka, M. Majka, D. Pratico et al., “Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells,” Experimental Hematology, vol. 30, no. 5, pp. 450–459, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. H. K. Kim, K. S. Song, J. Chung, K. R. Lee, and S. Lee, “Platelet microparticles induce angiogenesis in vitro,” The British Journal of Haematology, vol. 124, no. 3, pp. 376–384, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Varon and E. Shai, “Role of platelet-derived microparticles in angiogenesis and tumor progression,” Discovery Medicine, vol. 8, no. 43, pp. 237–241, 2009. View at Google Scholar · View at Scopus
  50. S. P. Ardoin, J. C. Shanahan, and D. S. Pisetsky, “The role of microparticles in inflammation and thrombosis,” Scandinavian Journal of Immunology, vol. 66, no. 2-3, pp. 159–165, 2007. View at Publisher · View at Google Scholar · View at Scopus